Home > News > Industry > Pharma News > Nephrocare India raises...

Nephrocare India raises Rs 8.08 crore in pre-IPO round

The fresh infusion of capital will fuel Nephrocare India's target of establishing 22 high-end kidney care facilities across India by March 2026.

By - Ruchika Sharma
Published On 2024-01-01 07:40 GMT   |   Update On 2024-03-27 07:51 GMT

Kolkata: Nephrocare India, a Kolkata-based comprehensive renal care institution, has raised Rs 8.08 crore in its pre-IPO round paving the way for its expansion plans, the company said on Friday. The funding saw participation from marquee investors, who include former HDFC chairman Deepak Parekh, HDFC Securities chairman Bharat Shah, and founder and MD of Macleods Pharmaceuticals Rajendra...

Login or Register to read the full article
Register Now

Kolkata: Nephrocare India, a Kolkata-based comprehensive renal care institution, has raised Rs 8.08 crore in its pre-IPO round paving the way for its expansion plans, the company said on Friday.

The funding saw participation from marquee investors, who include former HDFC chairman Deepak Parekh, HDFC Securities chairman Bharat Shah, and founder and MD of Macleods Pharmaceuticals Rajendra Agarwal, it said.

The fresh infusion of capital will fuel Nephrocare India's target of establishing 22 high-end kidney care facilities across India by March 2026. Four centres are expected to be operational by the end of the current fiscal, the company said in a statement.
Its long-term vision is to establish 300 Nephrocare centres across the country within the next 8-10 years.
Highlighting the critical need for such expansion, company officials pointed out the vast demand for kidney care units in India, the statement said.
With an estimated seven crore patients struggling with chronic kidney diseases and only around 12,881 haemodialysis centers nationwide, access to proper treatment remains severely limited,
Nearly one in eleven Indians are susceptible to renal failure which is often driven by diabetes and hypertension, the officials said.
India, dubbed the 'diabetes capital of the world', adds approximately 2.5 lakh new dialysis-dependent patients annually due to advanced kidney conditions, they added.

Read also: Emcure Pharma aims to raise USD 400- USD 500 million from IPO planned for next year

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Roche gets USFDA Breakthrough Therapy Designation for Inavolisib for breast cancer with mutation
SII ships first set of R21/Matrix-M Malaria Vaccine doses to Africa
Biocon Biologics forays into US Ophthalmology market with USFDA nod for Yesafili
BMS Gets CDSCO Panel Nod to Study Deucravacitinib
Biocon net profit declines 57 percent to Rs 136 crore in Q4
Johnson & Johnson to acquire Proteologix for USD 850 million in cash
Glenmark Pharma gets USFDA nod for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution
Sun Pharma, Dr Reddy's Labs, Aurobindo recall products in US over manufacturing issues